SG11202004895UA - Optimised compounds - Google Patents
Optimised compoundsInfo
- Publication number
- SG11202004895UA SG11202004895UA SG11202004895UA SG11202004895UA SG11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA SG 11202004895U A SG11202004895U A SG 11202004895UA
- Authority
- SG
- Singapore
- Prior art keywords
- optimised
- compounds
- optimised compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017905128A AU2017905128A0 (en) | 2017-12-21 | Optimised compounds | |
AU2018901056A AU2018901056A0 (en) | 2018-03-29 | Optimised compounds (2) | |
AU2018903597A AU2018903597A0 (en) | 2018-09-25 | Optimised compounds (3) | |
PCT/AU2018/051397 WO2019119067A1 (en) | 2017-12-21 | 2018-12-21 | Optimised compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004895UA true SG11202004895UA (en) | 2020-06-29 |
Family
ID=66992416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004895UA SG11202004895UA (en) | 2017-12-21 | 2018-12-21 | Optimised compounds |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210230217A1 (en) |
EP (1) | EP3728289A4 (en) |
JP (2) | JP7439367B2 (en) |
KR (1) | KR20200101428A (en) |
CN (1) | CN111491943A (en) |
AU (1) | AU2018391325B2 (en) |
BR (1) | BR112020012360A2 (en) |
CA (1) | CA3085377A1 (en) |
IL (1) | IL275360B2 (en) |
SG (1) | SG11202004895UA (en) |
WO (1) | WO2019119067A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019119069A1 (en) * | 2017-12-21 | 2019-06-27 | Ena Therapeutics Pty Ltd | Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent |
BR112021025630A8 (en) | 2019-06-26 | 2023-04-11 | Axelia Oncology Pty Ltd | NEW MOLECULES |
AU2021278377A1 (en) * | 2020-05-26 | 2022-12-15 | Ena Respiratory Pty Ltd | Treatment of coronavirus |
JP2023531387A (en) | 2020-06-26 | 2023-07-24 | イーナ レスパラトリー ピーティーワイ リミテッド | branched lipid compounds |
JP2024532434A (en) * | 2021-09-02 | 2024-09-05 | イーナ レスパラトリー ピーティーワイ リミテッド | formulation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011119759A1 (en) * | 2010-03-23 | 2011-09-29 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
WO2016037240A1 (en) * | 2014-09-12 | 2016-03-17 | The University Of Melbourne | Immunological reagent |
CN110461351B (en) * | 2017-03-31 | 2024-03-26 | 艾娜呼吸私人有限公司 | Treatment of respiratory tract infections with TLR2 agonists |
WO2019119069A1 (en) * | 2017-12-21 | 2019-06-27 | Ena Therapeutics Pty Ltd | Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent |
-
2018
- 2018-12-21 SG SG11202004895UA patent/SG11202004895UA/en unknown
- 2018-12-21 EP EP18890144.1A patent/EP3728289A4/en active Pending
- 2018-12-21 IL IL275360A patent/IL275360B2/en unknown
- 2018-12-21 CA CA3085377A patent/CA3085377A1/en active Pending
- 2018-12-21 JP JP2020534433A patent/JP7439367B2/en active Active
- 2018-12-21 US US16/768,341 patent/US20210230217A1/en active Pending
- 2018-12-21 KR KR1020207021016A patent/KR20200101428A/en not_active Application Discontinuation
- 2018-12-21 BR BR112020012360-9A patent/BR112020012360A2/en unknown
- 2018-12-21 AU AU2018391325A patent/AU2018391325B2/en active Active
- 2018-12-21 CN CN201880081904.8A patent/CN111491943A/en active Pending
- 2018-12-21 WO PCT/AU2018/051397 patent/WO2019119067A1/en unknown
-
2023
- 2023-10-02 JP JP2023171495A patent/JP2024001114A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3728289A1 (en) | 2020-10-28 |
KR20200101428A (en) | 2020-08-27 |
IL275360A (en) | 2020-07-30 |
EP3728289A4 (en) | 2021-10-13 |
IL275360B1 (en) | 2023-06-01 |
US20210230217A1 (en) | 2021-07-29 |
AU2018391325A1 (en) | 2020-06-18 |
BR112020012360A2 (en) | 2020-11-24 |
AU2018391325B2 (en) | 2024-07-11 |
JP2024001114A (en) | 2024-01-09 |
JP7439367B2 (en) | 2024-02-28 |
CN111491943A (en) | 2020-08-04 |
WO2019119067A1 (en) | 2019-06-27 |
CA3085377A1 (en) | 2019-06-27 |
JP2021506915A (en) | 2021-02-22 |
IL275360B2 (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201708456D0 (en) | Senolytic compounds | |
GB201704327D0 (en) | Compounds | |
GB201700814D0 (en) | Compounds | |
GB201715342D0 (en) | Compounds | |
PT3612519T (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
GB201704325D0 (en) | Compounds | |
IL275360A (en) | Optimised compounds | |
GB201713962D0 (en) | Compounds | |
GB201716871D0 (en) | Compounds | |
IL292485B2 (en) | Pyridylpyridone compounds | |
GB201707938D0 (en) | Compounds | |
GB201706162D0 (en) | Compounds | |
GB201715786D0 (en) | Compounds | |
GB201707856D0 (en) | Compounds | |
GB201702221D0 (en) | Compounds | |
GB201716369D0 (en) | Compounds | |
GB201707852D0 (en) | Compounds | |
GB201703282D0 (en) | Compounds | |
AU2017905128A0 (en) | Optimised compounds | |
GB201717050D0 (en) | Compounds | |
GB201716688D0 (en) | Compounds | |
GB201716352D0 (en) | Compounds | |
GB201716374D0 (en) | Compounds | |
GB201716392D0 (en) | Compounds | |
GB201713318D0 (en) | Compounds |